Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cyclerion Therapeutics (CYCN) EPS (Basic) (2019 - 2025)

Cyclerion Therapeutics (CYCN) has disclosed EPS (Basic) for 6 consecutive years, with -$0.34 as the latest value for Q3 2025.

  • For Q3 2025, EPS (Basic) changed N/A year-over-year to -$0.34; the TTM value through Sep 2025 reached -$1.45, changed N/A, while the annual FY2023 figure was $3.14, 410.41% up from the prior year.
  • EPS (Basic) hit -$0.34 in Q3 2025 for Cyclerion Therapeutics, up from -$0.54 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $5.53 in Q3 2023 and bottomed at -$6.16 in Q2 2022.
  • Average EPS (Basic) over 4 years is -$0.44, with a median of -$0.32 recorded in 2022.
  • Year-over-year, EPS (Basic) crashed 1268.89% in 2022 and then surged 2405.61% in 2023.
  • Cyclerion Therapeutics' EPS (Basic) stood at -$0.24 in 2021, then surged by 33.33% to -$0.16 in 2022, then soared by 3558.42% to $5.53 in 2023, then plummeted by 106.12% to -$0.34 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.34, -$0.54, and -$0.57 for Q3 2025, Q2 2025, and Q1 2025 respectively.